Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
News Jan 29, 2015
Horizon Discovery Group plc has announced that the Company’s Chief Executive Officer, Dr. Darrin Disley, has been awarded Entrepreneur of the Year at last night’s Quoted Company Awards 2015 in London.
The Quoted Company Awards, now in its 11th year, recognizes the achievements of quoted companies listed outside of the FTSE 350 and their key directors.
Dr. Disley has overseen a transformational year for Horizon, during which the company transitioned from a private UK life science business employing 85 staff on a single 18,000 sq. ft. site in Cambridge to a publically-listed international life science group employing 200 staff across over 85,000 sq. ft. of facilities located in the UK, Austria and the United States.
Under his leadership, Horizon listed on AIM market of the London Stock Exchange in March 2014, when the company was able to raise £68.6m, nearly three times the initial target. Since the IPO, Dr. Disley has driven Horizon’s growth through a series of targeted acquisitions into high value areas of the personalized medicines space: CombinatoRx based in Cambridge, Massachusetts; SAGE Labs based in St Louis, Missouri and Boyertown, Pennsylvania; and most recently Haplogen Genomics located in Vienna, Austria. He has also expanded the suite of products and services available to Horizon’s customers, bolstered the company’s intellectual property position, and delivered high-value contracts with leading life science companies, all contributing to growing revenues and creating shareholder value.
Dr. Disley is also an active entrepreneur and leader in the life science community outside of his role at Horizon, where he invests and provides guidance and mentoring to help develop promising young companies. He is also a strong advocate of the UK Life Sciences Sector and is a frequent speaker on the topic.
Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery, commented: “To be recognized as an innovator and leader by my peers is a tremendous honor. This has been an incredibly dynamic and exciting year for me and my colleagues at Horizon, and it is a testament to them that we have been able to be as successful as we have and to be as well positioned as we are for the future.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019